Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Efficacy and Quality of Life Outcome of Combined Epilepsy Surgery with RNS Placement
Epilepsy/Clinical Neurophysiology (EEG)
P5 - Poster Session 5 (11:45 AM-12:45 PM)
9-002

Surgical resection and LiTT are standard treatments for refractory epilepsy, but these options can be limited by eloquent cortex and seizure multifocality. Previous studies have suggested RNS may be used in conjunction with resective surgery (RNS+R) or LiTT (RNS+LiTT) as a new combination of treatments. Besides seizure control, quality of life and psychiatric symptoms including depression and anxiety are considered as important outcome evaluation after epilepsy surgery.

Retrospectively review clinical outcomes in patients treated with resection or Laser interstitial Thermal Therapy (LiTT) immediately (< 90 days) after implantation of RNS.

34 patients that had RNS+R or RNS+LiTT at our center were reviewed and 10 were excluded. The decision of dual procedures was made prior to surgery. Patients received RNS+R had both resective surgery and RNS placement in the same procedure. Patients received RNS+LiTT had several weeks gap between the RNS placement and LiTT due to neurosurgical logistics. Clinical follow-ups were performed at 12, 18, 24, 36 and 48 months for evaluation of seizure frequency. Patient health questionnaire-9 (PHQ-9) is used as a depression assessment. Quality of life in epilepsy questionnaire (QOLIE-31) was used as scoring for evaluation of general quality of life.  

Among the 24 patients that had RNS+R or RNS+LiTT, 22 patients (91.6%) showed improved seizure frequency at the last follow up. Fourteen patients had PHQ-9 evaluation and the average score was 5.85±6.29 (mean±SD), among which nine were between 0-4 (minimal depression), one was between 5-9(mild depression), three were between 10-14(moderate depression), one was 15-19(moderately severe depression) and none was 20-27(severe depression). QOLIE-31 done in eight patients showed average score of 65.61 ± 18.09 (mean±SD) in last follow-up visit.

Our study showed significant seizure control rate of RNS+R or RNS+LiTT therapy in refractory epilepsy patients. It also suggestive for promising psychiatric outcomes and quality of life scoring after surgery.

Authors/Disclosures
Jie Pan, MD
PRESENTER
Dr. Pan has nothing to disclose.
Shazia Mirza, MBBS (Baylor Scott & White Health) Dr. Mirza has nothing to disclose.
Mark A. Agostini, MD (U.T. Southwestern Medical Center) Dr. Agostini has nothing to disclose.
Sasha Alick-Lindstrom, MD, FAAN, FACNS,FAES (UT Southwestern Medical Center) Dr. Alick-Lindstrom has nothing to disclose.
Rohit Das, MD, FAAN (VA Portland Healthcare System) Dr. Das has received personal compensation for serving as an employee of Concentra. Dr. Das has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for janicek. The institution of an immediate family member of Dr. Das has received research support from NIH.
Kan Ding, MD (UT Southwestern Medical Center) The institution of Dr. Ding has received research support from National Institute of Aging. The institution of Dr. Ding has received research support from NINDS.
Alexander G. Doyle, MD (University of Texas SW Medical School) Dr. Doyle has nothing to disclose.
Marisara Dieppa, MD (University of Texas SW Medical School) Dr. Dieppa has nothing to disclose.
Ryan Hays, MD, MBA, FAAN, FAES (UT Southwestern Medical Center) Dr. Hays has nothing to disclose.
J. H. Harvey, DO (UT Southwestern Medical Center) Dr. Harvey has received personal compensation for serving as an employee of RSC Diagnostics. The institution of Dr. Harvey has received research support from GW Pharmaceuticals. The institution of Dr. Harvey has received research support from Cerevel Pharmaceuticals. The institution of Dr. Harvey has received research support from UCB Pharmaceuticals.
Bradley Lega, MD (UT Southwestern) The institution of Bradley Lega has received research support from NIH.
Irina Podkorytova No disclosure on file
Rodrigo Zepeda Garcia, MD (University of Texas Southwestern) The institution of Dr. Zepeda Garcia has received research support from NIH.
Ghazala Perven, MD (UT Southwestern Medical Center) Dr. Perven has nothing to disclose.